Psilocybin treatment is currently available through a small number of legal pathways: state-licensed service centers in Oregon, an emerging program in Colorado, clinical trials across the U.S., authorized prescribers in Australia, and retreat centers in a handful of other countries. The route that makes sense for you depends on where you live, what condition you’re hoping to address, and what you’re willing to spend.
Oregon’s Licensed Service Centers
Oregon is the first U.S. state where adults can walk into a licensed facility and receive psilocybin legally, no diagnosis required. Service centers began opening in the summer of 2023 under Ballot Measure 109, which directed the Oregon Health Authority to build a licensing and regulatory system from scratch. The program is open to anyone 21 and older.
The process works like this: you contact a licensed service center directly (the Oregon Health Authority publishes a licensee directory on its website), complete a screening, attend a preparation session, go through a supervised dosing session, and follow up with integration. You do not need a prescription or a referral from a doctor. Each center sets its own protocols and pricing, so the experience and cost vary. The state does not regulate what centers charge, and current prices typically range from roughly $1,000 to $3,500 for a full session cycle. Insurance does not cover it.
A licensed facilitator stays with you throughout the dosing session, which generally lasts six to eight hours. The facilitator’s role is supportive, not directive. They help you feel safe and grounded but don’t guide you through a specific therapeutic framework the way a psychotherapist would. If you’re looking for something closer to traditional therapy, ask the center about their facilitators’ training backgrounds before booking.
Colorado’s Program Is Still Launching
Colorado passed Proposition 122 in November 2022, creating a framework for supervised psilocybin use similar to Oregon’s model. Progress has been slower, though. The Natural Medicine Advisory Board was appointed in 2023, and licensing for facilitators opened in December 2024. Several facilitator training programs are already approved, based in cities including Boulder, Denver, Fort Collins, and Arvada. Licensed healing centers are expected to begin serving clients as the regulatory infrastructure continues rolling out through 2025 and into 2026.
If you’re in Colorado, keep an eye on the Division of Professions and Occupations website for updates on when centers open and how to find licensed facilitators.
Joining a Clinical Trial
Clinical trials remain one of the most accessible options for people outside Oregon and Colorado, and they’re free to participants. The FDA granted psilocybin Breakthrough Therapy designation in 2018 for treatment-resistant depression and in 2019 for major depressive disorder, which fast-tracked research. As of recent counts, over 130 clinical trials involving psilocybin have been registered, studying conditions ranging from depression and anxiety to alcohol use disorder, PTSD, and end-of-life distress.
To find a trial, search ClinicalTrials.gov for “psilocybin” and filter by your location, condition, and recruitment status. University medical centers in cities like Baltimore, New York, San Francisco, and London run many of the larger studies. Eligibility criteria vary by study but tend to be strict. Most trials exclude people with a personal or family history of psychotic disorders like schizophrenia or bipolar I disorder. Cardiovascular conditions, particularly uncontrolled high blood pressure, are also common exclusion criteria.
One important practical detail: nearly all psilocybin trials have historically required participants to taper off antidepressant medications, particularly SSRIs, before enrolling. SSRIs work on the same serotonin pathways that psilocybin acts on, and researchers have been concerned about blunted effects or unpredictable interactions. Some newer studies are beginning to test psilocybin in people who stay on their antidepressants, which would make treatment far more accessible for the millions of people who don’t want to risk the withdrawal effects of stopping their medication. If you’re on an SSRI or similar drug, ask the research team directly about their tapering requirements before committing.
What the Treatment Actually Looks Like
Whether you access psilocybin through a service center or a clinical trial, the structure follows a three-phase model: preparation, dosing, and integration.
Preparation typically involves one or more sessions before the dosing day. A facilitator or therapist reviews your history, explains what to expect physically and psychologically, and helps you set intentions. This is also where you build rapport with the person who will be in the room with you. The concept of “set and setting,” meaning your mindset going in and the physical environment around you, is emphasized heavily because both significantly shape the experience.
Dosing is a single session lasting roughly six to eight hours. You take psilocybin in a controlled, comfortable setting, usually a room designed to feel calm rather than clinical. A facilitator or therapist is present the entire time. The peak effects of psilocybin typically last three to five hours, with a gradual come-down after that. Experiences vary enormously. Some people describe profound emotional breakthroughs, vivid imagery, or a sense of deep connection. Others have difficult or frightening stretches. The facilitator’s job is to help you navigate whatever comes up.
Integration happens afterward, in at least one follow-up session. This is where you and your facilitator or therapist work through what came up during the experience: what it meant, what insights emerged, and how to translate any of that into lasting changes in your thinking or behavior. Many practitioners consider integration the most important phase, because the dosing session itself is only useful if you can make sense of it afterward.
The number and length of preparation and integration sessions vary widely between programs. Some offer a single session on each side, while others build in three or more. If you’re choosing between providers, more preparation and integration time generally means a more thorough experience.
Options Outside the United States
Australia became the first country to formally approve psilocybin as a prescription medicine. On July 1, 2023, the Therapeutic Goods Administration reclassified psilocybin as a controlled medicine specifically for treatment-resistant depression. Only authorized psychiatrists can prescribe it, and they must first get approval from a human research ethics committee and then from the TGA itself. This means access is limited to a small number of specialists, and the process is heavily regulated. It’s not something you can arrange quickly.
Several other countries have legal frameworks that allow psilocybin use in wellness or ceremonial settings, even if they haven’t created formal medical programs. Jamaica has no laws prohibiting psilocybin, and a well-established retreat industry operates there openly. The Netherlands permits psilocybin truffles (a different part of the same organism), which are sold legally and used at supervised retreat centers. Costa Rica and Peru also host retreat centers, often framed around indigenous ceremonial traditions.
The quality and safety of international retreats varies dramatically. Some are run by experienced professionals with medical screening protocols, trained facilitators, and integration support. Others are loosely organized with minimal oversight. If you’re considering a retreat abroad, look for programs that conduct medical and psychological screening before accepting you, have clear emergency protocols, and provide integration sessions after the experience.
Who Should Not Use Psilocybin
Psilocybin is not appropriate for everyone. People with a personal or family history of psychotic disorders, including schizophrenia and schizoaffective disorder, face a genuine risk of triggering a psychotic episode. This is the most consistently cited exclusion across clinical research and service programs. Bipolar disorder, particularly bipolar I with a history of mania, is also a common disqualifier.
Uncontrolled cardiovascular conditions raise safety concerns because psilocybin temporarily increases heart rate and blood pressure. If you have significant heart disease or uncontrolled hypertension, most programs will screen you out or require medical clearance.
The interaction with psychiatric medications deserves serious attention. SSRIs and other serotonin-acting antidepressants can dampen psilocybin’s effects and may carry theoretical risks when combined. Lithium in particular has been flagged for potentially dangerous interactions, including seizures. Any legitimate program will ask about your full medication list during screening. Be completely transparent about what you’re taking.
Practical Costs and Access Barriers
Cost is the biggest barrier for most people. Oregon service centers charge anywhere from $1,000 to $3,500 or more for a full session cycle, and no health insurance plan in the U.S. currently covers psilocybin services. In Australia, the out-of-pocket expense for authorized prescriber treatment is similarly high. International retreats range widely, from a few hundred dollars to $10,000 or more for luxury programs, plus travel costs.
Clinical trials are free, but access is limited by strict eligibility criteria, geographic proximity to research sites, and the time commitment of screening visits, medication washout periods, multiple therapy sessions, and follow-up assessments that can span months.
Some Oregon service centers have begun offering sliding-scale pricing or reduced-cost sessions for lower-income clients, so it’s worth asking directly. As Colorado’s program comes online and more centers open in Oregon, competition may gradually bring prices down, though psilocybin services will likely remain a significant out-of-pocket expense for the foreseeable future.